CrEAM-HD- At a Glance
  • Sponsored by : University Hospital, Lille
  • Official Title: Is Caffeine an Environmental Modifier in Huntington’s Disease?
  • Involves:Neurological, neuropsychological, neuroimaging evaluation and biological sample
  • Study type: Clinical Observational trial
  • phase: Not applicable 
  • Purpose : The aim of the study is to establish if caffeine consumption is associated with the evolution of the disease in premanifest HD.
  • Status: see trial sites below for details on recruitment status


Eligibility Criteria

Ages Eligible for Study:  21Years and older  (Adult, Older Adult)
Sexes Eligible for Study:  All
Accepts Healthy Volunteers: No


Inclusion Criteria

  • HD mutation carriers (>36 CAG)
  • premanifest (total motor UHDRS < 5)
  • estimated time to diagnosis between 3 and 10 years
  • adults older than 21 years (in order to exclude juvenile patients who begin the disease before 21 years)
  • informed consent signed
  • with a social protection

Exclusion Criteria

  • MRI contraindication
  • pregnant and lactating women
  • People under guardianship, trusteeship, deprive of freedom






Trial site: Hôpital Roger Salengro, CHRU.


Status: Recruiting 

Address: Lille, France



Contact: Not Available at the moment


Telephone: Not Available at the moment


Email:  Not Available at the moment